Judge Sets Deadline for Post-Trial Briefs In Zyprexa Case

Law360, New York (March 3, 2004, 12:00 AM EST) -- A federal judge has given both sides in the patent trial over Eli Lilly's Zyprexa schizophrenia drug until May 12 to file all of their post-trial briefs.

U.S. District Court Judge Richard L. Young last week also extended a stay barring the sale of generic Zyprexa until a verdict is handed down.

Young set the post-trial deadlines last week, after Lilly and the two main defendants couldn't agree to a schedule on their own.

Young ordered defendants Zenith Goldline Pharmaceuticals and Dr. Reddy's Laboratories to file...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.